Acumen Pharmaceuticals, Inc.
ABOS
$1.98
$0.052.59%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -19.37% | 90.06% | 102.96% | 160.05% | 143.73% |
| Gross Profit | 19.37% | -90.06% | -102.96% | -160.05% | -143.73% |
| SG&A Expenses | -9.43% | -4.60% | -4.15% | -3.18% | 3.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.83% | 71.24% | 70.87% | 114.20% | 101.17% |
| Operating Income | 17.83% | -71.24% | -70.87% | -114.20% | -101.17% |
| Income Before Tax | 11.13% | -99.40% | -93.61% | -125.22% | -129.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 11.13% | -99.40% | -93.61% | -125.22% | -129.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.13% | -99.40% | -93.61% | -125.22% | -129.72% |
| EBIT | 17.83% | -71.24% | -70.87% | -114.20% | -101.17% |
| EBITDA | 17.83% | -71.29% | -70.94% | -114.34% | -101.23% |
| EPS Basic | 11.85% | -97.78% | -91.31% | -117.44% | -107.37% |
| Normalized Basic EPS | 11.85% | -97.80% | -91.38% | -117.50% | -107.37% |
| EPS Diluted | 11.85% | -97.78% | -91.31% | -117.44% | -107.37% |
| Normalized Diluted EPS | 11.85% | -97.80% | -91.38% | -117.50% | -107.37% |
| Average Basic Shares Outstanding | 0.82% | 0.82% | 1.19% | 3.56% | 10.79% |
| Average Diluted Shares Outstanding | 0.82% | 0.82% | 1.19% | 3.56% | 10.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |